An exploratory study of metformin and rapamycin as maintenance therapy

(Impact Journals LLC) Volume 11, Number 21 of @Oncotarget reported that eligible patients with stable or responding mPDA after 6 months on chemotherapy were randomized 1:1 to metformin alone or with rapamycin, stratified by prior treatment with FOLFIRINOX. Metformin +/ rapamycin maintenance for mPDA was well-tolerated and several patients achieved stable disease associated with exceptionally long survival.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news